Reach out to Pi Health to help you find the right clinical trail
A Pilot, Open-label Study of Tislelizumab in Combination With Chemotherapy in First-line treatment of Unresectable/Metastatic Non-small Cell Lung Cancer or Recurrent/Metastatic Squamous Cell Head and Neck Cancer
Inclusion Criteria: Patients with advanced or metastatic NSCLC previously treated.
Principal Investigator: Dr. Venugopal Arroju
Exclusion Criteria: Patients with autoimmune disorders.
CTRI No: CTRI/2024/04/066248
A Study of Intravesical Bacillus Calmette-Guerin (BCG) in Combination With ALT-803 in Patients With Non-Muscle Invasive Bladder Cancer
Inclusion Criteria: Patients with non-muscle invasive bladder cancer.
Principal Investigator: Dr. Venugopal Arroju
Exclusion Criteria: Patients with active urinary tract infections.
CTRI No: CTRI/2024/07/070765
An open-label randomized trial of the efficacy and safety of zanidatamab with standard-of-care therapy against standard-of-care therapy alone for advanced HER2-positive biliary tract cancer
Inclusion Criteria: Patients with advanced HER2-positive biliary tract cancer.
Principal Investigator: Dr. Venugopal Arroju
Exclusion Criteria: Patients with uncontrolled heart disease.
CTRI No: CTRI/2024/08/072371